

Correction: MR imaging biomarkers evaluating vascular normalization window after anti-vessel treatment

Jun Yang¹, Chengde Liao¹, Yifan Liu¹, Guangjun Yang¹, Tengfei Ke¹, Yingying Ding¹ and Qinqing Li¹

¹Department of Radiology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming 650118, Yunnan, P.R. China

Published: May 05, 2022

Copyright: © 2022 Yang et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: In Figure 4, panel ‘E’ contains an accidental duplication of panel ‘D’. The corrected Figure 4 (panels ‘D’ through ‘G’), is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2018; 9:11964–11976. <https://doi.org/10.18632/oncotarget.22600>




Figure 4: Microvessel density and pericyte coverage in C6 glioma. (D–G) Immunohistochemical analysis representative examples of tumors on day 4 after bevacizumab treatment showed that a low density of microvasculature (CD34) and highly covered with perivascular cells (SMA) in the treatment group (E and G) on day 4 compared with control group (D and F). Images were acquired at 200× (D, E) or 100× (F, G) magnification. Scale = 50 μm.